Efficacy and Safety of Prehospital Diltiazem

被引:0
|
作者
Pil, Ellen [1 ]
Levy, Matthew [1 ]
Chizmar, Timothy [2 ]
Troncoso, Ruben [1 ]
Garfinkel, Eric [1 ]
Margolis, Asa [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA
[2] Maryland Inst Emergency Med Serv Syst MIEMSS, Baltimore, MD USA
关键词
ATRIAL-FIBRILLATION;
D O I
10.1080/10903127.2024.2326598
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective This study assesses the likelihood of clinical improvement and adverse events from EMS-administered diltiazem. Current prehospital protocols direct paramedics to administer diltiazem, a calcium channel blocker, to decrease the heart rate (HR) of symptomatic, hemodynamically stable patients with rapid atrial fibrillation. However, diltiazem can also cause systemic hypotension and bradycardia, which can precipitate end-organ injury. Methods To assess whether the rate control benefit of prehospital diltiazem outweighs the risk of adverse events, we conducted a retrospective chart review of all adult patients who received diltiazem from Maryland Advanced Life Support EMS clinicians between January 1, 2019, and March 31, 2022. Collected data included patient demographics, vital signs, diltiazem dose, transport times, administered medications, and procedures. The main outcomes were clinical improvement (HR <100 beats per minute or >= 20% decrease from the maximum HR) and adverse events (bradycardia or hypotension). Multivariable logistic regression was used for statistical analysis. Results During the study period, 2396 patients received prehospital diltiazem and 94% of these patients (n = 2254) were included in the study. Overall, 1414 (63.8%) patients improved clinically, 604 (27.3%) patients achieved rate control as defined by a HR of <100 beats per minute, and 78 patients (3.5%) experienced an adverse event. Patients over the age of 50 were less likely to clinically improve with diltiazem administration. Adverse events were more likely in patients with systolic blood pressures (SBP) less than 140 mmHg, patients with maximum HR of less than 120 beats per minute, and patients who received nitroglycerin. Conclusions Prehospital diltiazem is effective and safe for most patients. Adverse events are more likely in patients with baseline SBP less than 140 mmHg, HR less than 120 beats per minute, and concurrent nitroglycerin administration. Future opportunities for research include examining the relationship between adverse events and underlying etiology as well as investigating downstream outcomes.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Safety and efficacy of clopidogrel versus ticagrelor in acute coronary syndrome in the prehospital setting
    Szarpak, Lukasz
    Jaguszewski, Milosz J.
    Pruc, Michal
    Malysz, Marek
    Gasecka, Aleksandra
    Rafique, Zubaid
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 56 : 351 - 352
  • [22] Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield
    Wedmore, Ian S.
    Kotwal, Russ S.
    McManus, John G.
    Pennardt, Andre
    Talbot, Timothy S.
    Fowler, Marcie
    McGhee, Laura
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2012, 73 : S490 - S495
  • [23] Review article: Efficacy and safety of methoxyflurane analgesia in the emergency department and prehospital setting
    Grindlay, Joanne
    Babl, Franz E.
    EMERGENCY MEDICINE AUSTRALASIA, 2009, 21 (01) : 4 - 11
  • [24] SAFETY OF PREHOSPITAL NITROGLYCERIN
    WUERZ, R
    SWOPE, G
    MEADOR, S
    HOLLIMAN, CJ
    ROTH, GS
    ANNALS OF EMERGENCY MEDICINE, 1994, 23 (01) : 31 - 36
  • [25] Assessment of the efficacy, optimal dosage, and safety of diltiazem in early treatment of unstable angina pectoris
    Bai, R
    CLINICAL CARDIOLOGY, 2005, 28 (07) : 343 - 348
  • [26] SAFETY AND EFFICACY OF INTRAVENOUS DILTIAZEM IN ATRIAL FIBRILLATION WITH RAPID VENTRICULAR RESPONSE IN THE INPATIENT ENVIRONMENT
    Ryaboy, Ilya
    Askin, Cyrus A.
    Farhat-Sabet, Ardalon
    Fisher, Raymond
    Chung, Kevin K.
    Bush, Kelvin
    Thomas, Dustin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 448 - 448
  • [27] EFFICACY AND SAFETY OF INTRAVENOUS DILTIAZEM FOR TREATMENT OF ATRIAL-FIBRILLATION AND ATRIAL-FLUTTER
    SALERNO, DM
    DIAS, VC
    KLEIGER, RE
    TSCHIDA, VH
    SUNG, RJ
    SAMI, M
    GIORGI, LV
    AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (15): : 1046 - 1051
  • [28] MULTICENTER EVALUATION OF THE EFFICACY AND SAFETY OF SUSTAINED-RELEASE DILTIAZEM HYDROCHLORIDE FOR THE TREATMENT OF HYPERTENSION
    WOEHLER, TR
    EFF, J
    GRANEY, W
    HEALD, D
    ZIEMNIAK, J
    MAGNER, D
    CLINICAL THERAPEUTICS, 1992, 14 (02) : 148 - 157
  • [29] COMPARISON OF EFFICACY AND SAFETY OF LONG-TERM ANTIHYPERTENSIVE THERAPY WITH DILTIAZEM VS HYDROCHLOROTHIAZIDE
    ZAWADA, ET
    CHEST, 1986, 89 (06) : S495 - S495
  • [30] LONG-TERM EFFICACY AND SAFETY OF SUSTAINED-RELEASE DILTIAZEM IN THE TREATMENT OF HYPERTENSION
    MYBURGH, DP
    SOUTH AFRICAN MEDICAL JOURNAL, 1990, 78 (08): : 456 - 457